RxDoctor Payments Data

Maria E Santana, MD

Infectious Disease · Elmhurst, NYNPI 1841222957

Payments from drug & device makers

$3,210in general payments, 2019–2025

Across 144 payments — averaging $22.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$951
  • Johnson & Johnson$859
  • Viiv Healthcare Company$555
  • Janssen Products, LP$530
  • Relievant Medsystems, Inc.$117
  • Amgen$71
  • plus $127 from 4 others

What the payments were for

  • Food & beverage$2,64082%
  • Education$57018%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,210 in reported general payments places this provider in the 75th percentile of 799 infectious disease providers in New York.

See all infectious disease providers in New York

Medicare billing

Part B allowed, 2024
$2,878
Medicare patients
15
Services billed
29

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala202$801,720
GenvoyaElviteg/Cob/Emtri/Tenof Alafen116$566,095
JulucaDolutegravir/Rilpivirine154$551,688
TivicayDolutegravir Sodium113$291,781
DovatoDolutegravir Sodium/Lamivudine82$258,490
OdefseyEmtricitab/Rilpiviri/Tenof Ala50$182,479
DescovyEmtricitabine/Tenofov Alafenam71$157,920
CabenuvaCabotegravir/Rilpivirine20$126,220
PrezcobixDarunavir/Cobicistat49$120,875
IsentressRaltegravir Potassium39$71,281
SymtuzaDarunavir/Cob/Emtri/Tenof Alaf14$58,293
Darunavir31$38,480
TrulicityDulaglutide20$34,902
EdurantRilpivirine Hcl17$24,704
VascepaIcosapent Ethyl42$22,945

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy, Genvoya, Descovy$951$1,525,734389 claims
Viiv Healthcare CompanyJuluca, Tivicay, Dovato, Cabenuva$555$1,228,180369 claims
Johnson & JohnsonPrezcobix$859$120,87549 claims
Janssen Products, LPSymtuza$530$58,29314 claims
AbbVieNorvir, Synthroid$21$4,22524 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 799 infectious disease providers in New York.

Other infectious disease in Elmhurst

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →